BG-002 is under clinical development by BioSyngen and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BG-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BSG-002 is under development for the treatment of Epstein-Barr virus (EBV) related cancer including gastric cancer, lymphoma, multiple sclerosis, nasopharyngeal cancer. The therapeutic candidate comprises cytotoxic T cells which are genetically modified with viral vectors to express T cell receptors (TCR).
For a complete picture of BG-002’s drug-specific PTSR and LoA scores, buy the report here.